Invida to Present at the Rodman & Renshaw Annual Global Investment Conference

Share Article

Invida Group Pte Ltd, the leading specialty biopharmaceutical company focused on the commercialization of healthcare products throughout Asia Pacific, today announced that the company has been selected to present at the 2010 Rodman & Renshaw Annual Global Investment Conference.

Invida Group Pte Ltd, the leading specialty biopharmaceutical company focused on the commercialization of healthcare products throughout Asia Pacific, today announced that the company has been selected to present at the 2010 Rodman & Renshaw Annual Global Investment Conference. The presentation will occur on Tuesday, May 18, 2010 at 12:20 PM in London, UK and will be webcast live and available on the conference's website at http://www.wsw.com/webcast/rrshq17/invida. CEO John A. Graham will provide an updated overview of the Company, its strategy for 2010 and key partnering opportunities for growth in Asia Pacific.

John A. Graham, Chief Executive Officer of Invida, said, “During this time of focused growth for Invida, we look forward to the opportunity to provide an update on our corporate developments and future plans for the Company. The Rodman conference will provide us with an excellent opportunity to meet with potential partners, as well as members of the financial and investment community, and to update our stakeholders on our plans for continued success.”

About Invida Group Pte Ltd
Invida improves the lives of patients in Asia by commercializing differentiated pharmaceutical products of superior quality - the result of which will allow all our stakeholders to prosper. We do this through our proven brand marketing and sales know-how, strong expertise across a number of key therapeutic categories and deep experience in all critical Asian markets. Comprehensive functional capabilities provide rapid market access delivered by our passionate team of professionals.

With more than 4,000 employees in 13 markets in Asia Pacific, Invida operates across the commercial value chain from regulatory approval and product launch to lifecycle management. We manage a portfolio of proprietary healthcare brands as well as licensed products from small biotech firms and large multinational companies. Partnering is a critical component of Invida’s business model. We collaborate closely with our partners in developing effective strategies and put our extensive experience behind maximizing the potential of the assets entrusted to us.

# # #

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Lisa Rivero
LaVoie Group, Inc.
+1 (978) 745-4200 ext. x106
Email >

Liz Pingpank
LaVoie Group, Inc.
+1 (978) 745-4200 ext. x104
Email >
Visit website